Covid-19 vaccine effectiveness during Omicron BA.2 pandemic in Shanghai: A cross-sectional study based on EMR
Open Access
- 11 November 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (45) , e31763
Abstract
Large-scale vaccination against the spread and mutation of COVID-19 is being implemented in many countries. We aimed to assess the effectiveness of certain vaccines (87.35% inactivated), mainly Sinovac – CoronaVac and Sinopharm (Beijing) – BBIBP-CorV, during the Omicron BA.2 pandemic by cross-sectional study. The study was conducted in a cabin hospital of Shanghai, China. A total of 1194 Covid-19 patients infected with Omicron BA.2 were enrolled and epidemiological survey information was collected from the subjects through electronic medical records and questionnaires, from March 23th to April 1st in 2022. Vaccine effectiveness was reflected by the occurrence of multi-dimensional symptoms while adjusting for confounding variables. In the unstandardized vaccinated group, the Covid-19 vaccine effectiveness of Omicron BA.2 in the male group was higher than in the female group (P = .0171). In the standardized vaccinated group, vaccine effectiveness in [20, 40) age group was higher than in other age groups (P = .0002). Adjusting for gender and age, Covid-19 vaccine effectiveness of Omicron BA.2 at the specific level was 87.42% (95% confidence interval [CI], 72.35–94.28, P < .0001), and 62.65% (95% CI, 1.47–85.84, P = .047) in the unstandardized vaccinated and the standardized vaccinated group, respectively. Covid-19 vaccine effectiveness of Omicron BA.2 was not apparent at the general level but remained effective for the specific symptom. Further development for the Covid-19 vaccine is necessary.Keywords
This publication has 14 references indexed in Scilit:
- Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in QatarNew England Journal of Medicine, 2021
- Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trialsThe Lancet Infectious Diseases, 2021
- Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemicThe Lancet, 2021
- Covid-19 Vaccine Effectiveness in New York StateNew England Journal of Medicine, 2021
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort studyThe Lancet, 2021
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in ChileNew England Journal of Medicine, 2021
- Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control studyBMJ, 2021
- Evolution patterns of SARS-CoV-2: Snapshot on its genome variantsBiochemical and Biophysical Research Communications, 2021
- Global impact of varicella vaccination programsHuman Vaccines & Immunotherapeutics, 2018
- The evolution of RNA viruses: A population genetics viewProceedings of the National Academy of Sciences, 2000